{"id":"W4321794008","doi":"10.1016/j.jtho.2023.02.003","title":"Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; BC Cancer Agency; Saskatchewan Cancer Agency; CancerCare Manitoba; Alberta Cancer Foundation; Juravinski Cancer Centre; Centre Hospitalier de l’Université de Montréal; Canadian Cancer Society; University Health Network","funders":"EMD Serono; Merck Canada; Servier; Canadian Cancer Society; Ipsen; BeiGene; Les Laboratories Pierre Fabre; Astellas Pharma; Novocure; Eisai; Jazz Pharmaceuticals; Merck KGaA; Sanofi; GlaxoSmithKline; Amgen; Pfizer; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Mesothelioma; Pemetrexed; Confidence interval; Internal medicine; Lung cancer; Interim analysis; Interim; Oncology; Clinical trial; Cancer; Chemotherapy; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002738279,0.001372909,0.00208188,0.0004246305,0.0008749611,0.001692891,0.001297021,0.003562179,0.03948147],"category_scores_gemma":[0.004648771,0.0006861028,0.002324077,0.0007344161,0.0006198123,0.00078071,0.0004799721,0.004576828,0.006034574],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003361906,"about_ca_system_score_gemma":0.007928758,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02395037,"about_ca_topic_score_gemma":0.08914683,"domain_scores_codex":[0.9990448,0.0004283252,0.00005426793,0.0001312263,0.0001861597,0.0001551312],"domain_scores_gemma":[0.9977344,0.0005699092,0.0004542852,0.0001219718,0.0003636032,0.0007558495],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2606224,0.002372119,0.001769623,0.006157575,0.003973209,0.0002120949,0.00009231836,0.0005623377,0.002413746,0.0009789011,0.6111482,0.1096975],"study_design_scores_gemma":[0.857388,0.0113689,0.007479579,0.0006666377,0.002472451,0.0001237399,0.0000412299,0.0003327013,0.0004195387,0.0006743093,0.1189761,0.00005673672],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"dataset","genre_gemma":"empirical","genre_scores_codex":[0.1612852,0.1370938,0.003692164,0.1880019,0.03400204,0.05202172,0.2595818,0.001797596,0.1625238],"genre_scores_gemma":[0.4100735,0.07152345,0.01116624,0.1464455,0.02335038,0.03966462,0.1205908,0.0005598789,0.1766256],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.03948147,"threshold_uncertainty_score":0.1320786,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02884808156540722,"score_gpt":0.4260797057055907,"score_spread":0.3972316241401834,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}